We invite you to attend the Infectious Diseases World Summit, which will take place on June 1-3, 2016 in San Diego, CA.

We are pleased to invite you to attend GTCbio's Infectious Diseases World Summit, which will take place June 1-3, 2016 in San Diego, CA. This event seeks to provide a forum for leaders to get the most comprehensive and wide-reaching perspective on issues, challenges, and advances in the field. The Summit is comprised of the following four conferences happening over the course of three days:

5th Antiviral Research & Development
Top researchers will share their experiences with new inhibitory mechanisms, longer acting drugs, and strategies en route for cures. Delegates have the unique opportunity to network with colleagues from different sectors and gain fresh perspective on the research in antiviral drugs.


2nd Bugs & Drugs: Antibacterial Drug Discovery
The increase and spread of antibiotic-resistance and the reduced investment by the pharmaceutical industry have given us an unsettling glimpse of a post-antibiotic era. Ultimately, it is the goal of the scientific community, and certainly that of the attendees, to forestall that event and to prevent the serious consequences that would come inevitably from it.


14th Vaccines Research & Development
Newly emerging infections have opened up dialogue about the need for novel treatments and government response to such infections. As we continue to search for solutions, we must review the lessons learned from research and industry response in order to overcome the current challenges.


13th Anti-Infectives Partnering & Deal-Making
Over the years, the anti-Infectives field has faced the same challenges in areas such as pricing and reimbursement and overcoming resistance in diseases. However, drug approvals over the past year and President Obama's recent proposal to spend $1.2 billion to address antimicrobial resistance are indications that the field is still changing and evolving.

In recent years, the field of infectious diseases has faced repeated challenges, and areas such as pricing and reimbursement, regulatory, and the discovery of novel antibiotics have yet to be overcome.

However, recent deals and the reemergence of big pharma in the space has signaled that the landscape of infectious diseases is shifting: why is there a renewed interest in this field? What will it mean for biotech companies, government agencies, and other players? This Summit seeks to highlight all stages of the field, from research and novel therapeutics, to commercialization aspects and market activity. Colleagues from academia, industry, and government will gather at the interface of infectious diseases drug development to address current issues and find solutions to move the field forward into the future.